Compare CNM & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNM | KYMR |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Durable Goods | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 9.6B |
| IPO Year | 2021 | 2020 |
| Metric | CNM | KYMR |
|---|---|---|
| Price | $43.93 | $106.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 26 |
| Target Price | $61.55 | ★ $107.72 |
| AVG Volume (30 Days) | ★ 2.1M | 671.1K |
| Earning Date | 06-09-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.45 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $7,647,000,000.00 | $39,211,000.00 |
| Revenue This Year | $4.89 | $10.61 |
| Revenue Next Year | $4.21 | $8.17 |
| P/E Ratio | $76.58 | ★ N/A |
| Revenue Growth | ★ 2.77 | N/A |
| 52 Week Low | $42.50 | $36.88 |
| 52 Week High | $67.18 | $130.05 |
| Indicator | CNM | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 41.08 | 48.35 |
| Support Level | $42.50 | $76.40 |
| Resistance Level | $54.69 | $120.37 |
| Average True Range (ATR) | 1.35 | 5.21 |
| MACD | -0.02 | -1.91 |
| Stochastic Oscillator | 33.57 | 5.87 |
Core & Main is a leading specialty distributor with a focus on water, wastewater, storm drainage, and fire protection products. The company provides solutions to municipalities, private water companies, and professional contractors across municipal, nonresidential, and residential end markets. The company's specialty products and services are used in the maintenance, repair, replacement, and construction of water and fire protection infrastructure.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.